Trimming This Small-Cap Biotech on Strength as We Eye the Chart
Here’s what we’re seeing technically ahead of next week’s earnings.
You've reached your free article limit
You've read 0 of 1 free Pro articles.
Readers can see below that Ocular Therapeutix (OCUL) will be the next name on our book to go to the tape with earnings, this coming Wednesday.
SoFi Technologies (SOFI) put together a great quarter and issued impressive guidance to get our season off to a good start. Next Thursday, both Aspen Aerogels (ASPN) and Peloton Interactive (PTON) will report, so we’ll have a busy week here at the $10,000 Portfolio.
I noticed something technically concerning OCUL ahead of the numbers.
Let’s go to the chart:
Readers will see that OCUL has now formed a Double Bottom pattern of bullish reversal that encompasses all of 2026 and reaches back into December 2025. The pattern bears an $11.70 pivot, which may be a bit much to ask for as we have a $12 price target, but the setup has suddenly turned more bullish looking, which is, finally, a positive.
Yes, the stock did just suffer a death cross, but appears to be testing its 21-day exponential moving average (EMA) from below, nonetheless. This could potentially get the swing crowd, who turned against the stock in September, re-invested.
Relative Strength has greatly improved over the past week or so and now threatens to reach for a neutral reading. Below the chart, within the daily moving average convergence divergence (MACD), the histogram of the 9-day EMA has gone positive (bullish) while the 12-day EMA has crossed over the 26-day EMA (bullish). The negative would be that both of those lines remain below the zero-bound, which does slow down the optimism just a bit.
We are sticking with our price target. Maybe, we’ll adjust next week. That said, we are going to shave the position just a little this morning, on this welcome strength.
Thursday’s Intention
– Sell 20 shares of OCUL at or close to the last sale of $7.39.
Wednesday’s Intentions vs. Actual Trades
– Sell 10 shares of ONDS at or around the last sale of $6.69. (Bought the most recent 10 shares at $6.10)
– Sold 10 shares of ONDS at $6.67.
– Sell 10 shares of PL at or around the last sale of $14.52. (Bought the most recent 10 shares at $13.43)
– Sold 10 shares of PL at $14.27.
– Sell 4 shares of RKLB at or around the last sale of $58.23. (Bought the most recent 4 shares at $51.315.)
– Sold 4 shares of RKLB at $57.46.
Upcoming Portfolio Earnings
Ocular Therapeutix (OCUL), Wednesday, November 4
Consensus: adjusted EPS of $-0.35 on revenue of $14.3M.
Aspen Aerogels (ASPN), Thursday, November 5
Consensus: adjusted EPS of $-0.07 on revenue of $72.1M.
Peloton Interactive (PTON), Thursday, November 5
Consensus: adjusted EPS of $0.13 on revenue of $552.7M.
Rocket Lab (RKLB), Monday, November 9
Consensus: adjusted EPS of $-0.02 on revenue of $257.2M.
Evolv Technologies (EVLV), Tuesday, November 10, Semper Fi
Consensus: adjusted EPS of $-0.02 on revenue of $45.6M.
Ondas Inc. (ONDS), Friday, November 13
Consensus: adjusted EPS of $-0.09 on revenue of $148.1M.
Planet Labs (PL), on or close to December 10
Consensus: adjusted EPS of $-0.03 on revenue of $104.5M.
Current Positions
Long 60 shares of ASPN at $5.1083. Target Price: $10. Last sale: $5.44.
Long 50 shares of EVLV at $5.33.92. Target Price: $7.50. Last sale: $4.79.
Long 170 shares of OCUL at $8.1627. Target Price: $12. Last sale: $7.39.
Short one OCUL $9 Dec 18th call at $0.80, Last sale: $0.27.
Long 300 shares of ONDS at $7.7485. Target Price: $12. Last sale: $6.70.
Long 100 shares of PL at $18.9497. Target Price: $20. Last sale: $14.00.
Short one PL $17 Nov 19th call at $1.70, Last sale: $0.25.
Long 70 shares of PTON at $5.0654. Target Price: $9. Last close: $5.28.
Long 10 shares of RKLB at $53.667. Target Price $84. Last close: $56.65.
Long 125 shares of SOFI at $15.9644. Target Price: $24. Last close: $16.73.
Cash: $873.21.
Portfolio Value: $9,086.80, -9.1% from inception on March 24.
At the time of publication, Guilfoyle was long ASPN, EVLV, OCUL, ONDS, PL, PTON, RKLB and SOFI.
